The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
News & Analysis: Bluebird Bio
Solid data from the biggest blood disease meeting of the year has the biotech flying high.
Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.
No-news anxiety-selling seems to be to blame for the biotech's woes.
The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.
Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.
Data presented by a competitor increased the risk to its most promising clinical-stage therapy.
In September and October, investors thought Amgen set the bar in multiple myeloma too high, but in November bluebird bio teased promising data of its own.
Early data from the American Society of Hematology meeting suggests the biotech's drug pipeline is as strong as ever.
The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.
The biotech keeps feeding its coffers.